"Small Animal Radiation Research Platform (SARRP) for Yale University".

项目概要： 我们机构的研究人员使用平移啮齿动物模型来检查辐射对小鼠的影响 自1955年以来，肿瘤和正常组织。今天我们的放射研究主要集中在致敏肿瘤 涉及通过引入新的小分子、抗体、免疫学或遗传疗法的放射疗法。 然而，标准的正电压输送装置不能概括临床辐射方案。他们 不提供剂量输送的准确性或均匀性、离散病变或器官的靶向、 正常组织，或了解组织照射所必需的剂量体积计算。小 动物辐射研究平台（SARRP）-200 PRO解决了这些局限性， 使用集成的锥形束CT扫描（CBCT）和图像引导的微照射的治疗计划。的 SARRP将被整合到耶鲁癌症中心辐照器核心中，其专门用途也将被 由PI和咨询委员会监督。该仪器将支持几个正在进行的NIH资助 癌症生物学研究项目，加强实验设计，改善数据分析， 解释。SARRP将如何增强正在进行的研究的例子是现成的。SARRP 将改善大脑内的目标定位，耶鲁大学的许多项目都在研究这个位置，以及其他 解剖部位它将能够提供放射外科手术，这是几个寻求复制的研究者所要求的。 每部分方案具有高辐射剂量的临床场景。它还将提供研究 辐射与正常组织和免疫系统的相互作用，并评估治疗反应， 局部、区域和远距离部位。使用SARRP引导的辐射递送也是可行的。 预计将招募新用户，为受训者提供这项技术的教育经验， 大大扩展了肿瘤生物学和放射科学的研究。

PROJECT SUMMARY: Investigators at our institution have used translational rodent models to examine the effects of radiation on tumors and normal tissues since 1955. Today our radiation research is largely focused on sensitizing tumors to radiation therapy by introducing novel small molecule, antibody, immunologic, or genetic therapies. However, standard orthovoltage delivery devices are unable to recapitulate clinical radiation protocols. They do not provide accuracy or homogeneity of dose delivery, targeting of discrete lesions or organs, sparing of normal tissues, or the dose-volume calculations essential for understanding tissue exposures. The small animal radiation research platform (SARRP)-200 PRO addresses these limitations and enables target-based treatment planning using an integrated cone beam CT scan (CBCT) and image guided micro-irradiation. The SARRP will be integrated in to the Yale Cancer Center Irradiator Core and its specialized use will also be overseen by the PI and an advisory committee. The instrument will support several ongoing NIH funded research projects in cancer biology, enhance experimental designs, and improve data analysis and interpretation. Examples of how the SARRP will augment ongoing research are readily available. The SARRP will improve target localization within the brain, a site investigated by many projects at Yale, as well as other anatomic sites. It will enable delivery of radiosurgery, required by several investigators that seek to reproduce clinical scenarios with high radiation dose per fraction regimens. It will also provide the ability to study the interactions of radiation with normal tissue and the immune system, and to evaluate therapeutic responses at local, regional, and distant sites following irradiation. The use of SARRP guided radiation delivery is also anticipated to recruit new users, provide educational experience with this technology for trainees, and significantly expand research in tumor biology and the radiation sciences.